Gerald F. Joyce elected to the Institute of Medicine at the National Academy of Sciences

October 20, 2014

Gerald F. Joyce Elected to the Institute of Medicine at the National Academy of Sciences

  • Honor recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health

  • Joyce recently joined Novartis as Director of the Genomics Institute of the Novartis Research Foundation (GNF)

  • His research focuses on the development of novel RNA and DNA enzymes and their potential application in clinical diagnostics and therapeutics

    La Jolla, CA, USA, 10 A. M., October 20, 2014 -Gerald F. Joyce, M.D., Ph.D., is elected to the Institute of Medicine (IOM), the US National Academies of Sciences announced following the IOM's 44th annual meeting.¹ Joyce is perhaps best known as one of the inventors of directed evolution technology and, more recently, for creating the first self-replicating RNA enzyme.

    "I am honored to join the IOM and look forward to working with my colleagues and health policy makers on tackling the challenges facing our nation's health care system," said Joyce.

    Earlier this month Joyce joined Novartis as Director of the Genomics Institute of the Novartis Research Foundation (GNF) in La Jolla, California. GNF, part of the Novartis Institutes for BioMedical Research (NIBR), embraces the complexity of biological systems. GNF researchers use cutting-edge technology--including automation and robotics developed at the institute--to take advantage of emerging large-scale, data-rich fields for drug discovery. With a robust blend of basic science, engineering, and drug discovery research expertise, GNF plays a vital role in NIBR's commitment to change the practice of medicine.

    "We are thrilled that Jerry has joined Novartis as the Director of GNF and congratulate him on his election to the Institute of Medicine," said Mark Fishman, President of the Novartis Institutes for BioMedical Research. "He is a pioneering physician scientist whose research is helping us bridge the gap between science and medicine in our mission to discover new medicines."

    Prior to joining GNF, Jerry served as Dean of the Faculty at The Scripps Research Institute. He will maintain his faculty position there with the Department of Chemistry. Jerry is a member of the U.S. National Academy of Sciences and the American Academy of Arts and Sciences.

    This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "potential," "look forward," "commitment," "mission," "will," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.

    About Novartis

    Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit

    Novartis is on Twitter. Sign up to follow @Novartis at



    Novartis Media Relations

    Central media line : +41 61 324 2200

    Eric Althoff
    Novartis Global Media Relations
    +41 61 324 7999 (direct)
    +41 79 593 4202 (mobile)

    Mariellen Gallagher
    Novartis Institutes for BioMedical Research
    +41 61 324 8137 (direct)
    +41 79 959 6899 (mobile)


    For Novartis multimedia content, please visit

    For questions about the site or required registration, please contact:

    Novartis Institutes for BioMedical Research

    Related Health Care Articles from Brightsurf:

    Study evaluates new World Health Organization Labor Care Guide for maternity care providers
    The World Health Organization developed the new Labor Care Guide to support clinicians in providing good quality, women-centered care during labor and childbirth.

    Six ways primary care "medical homes" are lowering health care spending
    New analysis of 394 U.S. primary care practices identifies the aspects of care delivery that are associated with lower health care spending and lower utilization of emergency care and hospital admissions.

    Modifiable health risks linked to more than $730 billion in US health care costs
    Modifiable health risks, such as obesity, high blood pressure, and smoking, were linked to over $730 billion in health care spending in the US in 2016, according to a study published in The Lancet Public Health.

    Spending on primary care vs. other US health care expenditures
    National health care survey data were used to assess the amount of money spent on primary care relative to other areas of health care spending in the US from 2002 to 2016.

    MU Health Care neurologist publishes guidance related to COVID-19 and stroke care
    A University of Missouri Health Care neurologist has published more than 40 new recommendations for evaluating and treating stroke patients based on international research examining the link between stroke and novel coronavirus (COVID-19).

    Large federal program aimed at providing better health care underfunds primary care
    Despite a mandate to help patients make better-informed health care decisions, a ten-year research program established under the Affordable Care Act has funded a relatively small number of studies that examine primary care, the setting where the majority of patients in the US receive treatment.

    International medical graduates care for Medicare patients with greater health care needs
    A study by a Massachusetts General Hospital research team indicates that internal medicine physicians who are graduates of medical schools outside the US care for Medicare patients with more complex medical needs than those cared for by graduates of American medical schools.

    The Lancet Global Health: Improved access to care not sufficient to improve health, as epidemic of poor quality care revealed
    Of the 8.6 million deaths from conditions treatable by health care, poor-quality care is responsible for an estimated 5 million deaths per year -- more than deaths due to insufficient access to care (3.6 million) .

    Under Affordable Care Act, Americans have had more preventive care for heart health
    By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health.

    High-deductible health care plans curb both cost and usage, including preventive care
    A team of researchers based at IUPUI has conducted the first systematic review of studies examining the relationship between high-deductible health care plans and the use of health care services.

    Read More: Health Care News and Health Care Current Events
  • is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to